tetano
Editor, Senior Moderator
Immunity
. 2021 Jul 2;S1074-7613(21)00262-4.
doi: 10.1016/j.immuni.2021.06.018. Online ahead of print.
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
Anthony T DiPiazza[SUP] 1 [/SUP], Sarah R Leist[SUP] 2 [/SUP], Olubukola M Abiona[SUP] 1 [/SUP], Juan I Moliva[SUP] 1 [/SUP], Anne Werner[SUP] 1 [/SUP], Mahnaz Minai[SUP] 3 [/SUP], Bianca M Nagata[SUP] 3 [/SUP], Kevin W Bock[SUP] 3 [/SUP], Emily Phung[SUP] 1 [/SUP], Alexandra Schäfer[SUP] 2 [/SUP], Kenneth H Dinnon 3rd[SUP] 2 [/SUP], Lauren A Chang[SUP] 1 [/SUP], Rebecca J Loomis[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Nancy J Sullivan[SUP] 1 [/SUP], Darin K Edwards[SUP] 4 [/SUP], Kaitlyn M Morabito[SUP] 1 [/SUP], John R Mascola[SUP] 1 [/SUP], Andrea Carfi[SUP] 4 [/SUP], Kizzmekia S Corbett[SUP] 1 [/SUP], Ian N Moore[SUP] 3 [/SUP], Ralph S Baric[SUP] 2 [/SUP], Barney S Graham[SUP] 5 [/SUP], Tracy J Ruckwardt[SUP] 6 [/SUP]
Affiliations
Abstract
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndrome (SARS) and MERS coronavirus vaccines. We used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 10, lethal challenge virus (MA10) mouse model of acute lung injury to evaluate the immune response and potential for immunopathology in animals vaccinated with research-grade mRNA-1273. Whole-inactivated virus or heat-denatured spike protein subunit vaccines with alum designed to elicit low-potency antibodies and Th2-skewed CD4[SUP]+[/SUP] T cells resulted in reduced viral titers and weight loss post challenge but more severe pathological changes in the lung compared to saline-immunized animals. In contrast, a protective dose of mRNA-1273 induced favorable humoral and cellular immune responses that protected from viral replication in the upper and lower respiratory tract upon challenge. A subprotective dose of mRNA-1273 reduced viral replication and limited histopathological manifestations compared to animals given saline. Overall, our findings demonstrate an immunological signature associated with antiviral protection without disease enhancement following vaccination with mRNA-1273.
Keywords: COVID-19; SARS-CoV-2; T cells; mRNA vaccine; mRNA-1273; neutralizing antibodies; protective immunity; type 2 responses; vaccine-associated enhanced respiratory disease.
. 2021 Jul 2;S1074-7613(21)00262-4.
doi: 10.1016/j.immuni.2021.06.018. Online ahead of print.
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
Anthony T DiPiazza[SUP] 1 [/SUP], Sarah R Leist[SUP] 2 [/SUP], Olubukola M Abiona[SUP] 1 [/SUP], Juan I Moliva[SUP] 1 [/SUP], Anne Werner[SUP] 1 [/SUP], Mahnaz Minai[SUP] 3 [/SUP], Bianca M Nagata[SUP] 3 [/SUP], Kevin W Bock[SUP] 3 [/SUP], Emily Phung[SUP] 1 [/SUP], Alexandra Schäfer[SUP] 2 [/SUP], Kenneth H Dinnon 3rd[SUP] 2 [/SUP], Lauren A Chang[SUP] 1 [/SUP], Rebecca J Loomis[SUP] 1 [/SUP], Seyhan Boyoglu-Barnum[SUP] 1 [/SUP], Gabriela S Alvarado[SUP] 1 [/SUP], Nancy J Sullivan[SUP] 1 [/SUP], Darin K Edwards[SUP] 4 [/SUP], Kaitlyn M Morabito[SUP] 1 [/SUP], John R Mascola[SUP] 1 [/SUP], Andrea Carfi[SUP] 4 [/SUP], Kizzmekia S Corbett[SUP] 1 [/SUP], Ian N Moore[SUP] 3 [/SUP], Ralph S Baric[SUP] 2 [/SUP], Barney S Graham[SUP] 5 [/SUP], Tracy J Ruckwardt[SUP] 6 [/SUP]
Affiliations
- PMID: 34270939
- PMCID: PMC8249710
- DOI: 10.1016/j.immuni.2021.06.018
Abstract
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of severe acute respiratory syndrome (SARS) and MERS coronavirus vaccines. We used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 10, lethal challenge virus (MA10) mouse model of acute lung injury to evaluate the immune response and potential for immunopathology in animals vaccinated with research-grade mRNA-1273. Whole-inactivated virus or heat-denatured spike protein subunit vaccines with alum designed to elicit low-potency antibodies and Th2-skewed CD4[SUP]+[/SUP] T cells resulted in reduced viral titers and weight loss post challenge but more severe pathological changes in the lung compared to saline-immunized animals. In contrast, a protective dose of mRNA-1273 induced favorable humoral and cellular immune responses that protected from viral replication in the upper and lower respiratory tract upon challenge. A subprotective dose of mRNA-1273 reduced viral replication and limited histopathological manifestations compared to animals given saline. Overall, our findings demonstrate an immunological signature associated with antiviral protection without disease enhancement following vaccination with mRNA-1273.
Keywords: COVID-19; SARS-CoV-2; T cells; mRNA vaccine; mRNA-1273; neutralizing antibodies; protective immunity; type 2 responses; vaccine-associated enhanced respiratory disease.